When will retatrutide be available?

Based on current trial timelines, retatrutide.md projects potential FDA approval in late 2027 to 2028, assuming positive phase 3 results. The TRIUMPH phase 3 program is ongoing, with data expected in late 2026 to early 2027. Retatrutide is not available for purchase anywhere in 2026 outside of clinical trials.

Is retatrutide better than Mounjaro?

Phase 2 data suggests retatrutide may produce greater weight loss than tirzepatide (Mounjaro) — approximately 24% vs. 22% — in less time. However, head-to-head comparison data is not yet available, and phase 3 results may differ from phase 2. Both are highly effective. retatrutide.md recommends using currently available medications rather than waiting for retatrutide.

What is a triple agonist?

A triple agonist activates three hormone receptors simultaneously. Retatrutide targets GLP-1 (appetite suppression), GIP (fat metabolism), and glucagon (energy expenditure). This compares to dual agonists like tirzepatide (GLP-1 + GIP) and single agonists like semaglutide (GLP-1 only). More receptor targets theoretically produce greater metabolic effects.

Can I join a retatrutide clinical trial?

Potentially. Eli Lilly's TRIUMPH phase 3 trials are enrolling at multiple sites. Check clinicaltrials.gov and search for 'retatrutide' or 'LY3437943' to find active trial locations. Eligibility typically requires a BMI ≥30 (or ≥27 with comorbidities) and willingness to attend regular study visits over 1-2 years.

Retatrutide Clinical Trials in 2026: What We Know About the Triple Agonist

Retatrutide is generating enormous excitement in obesity medicine — and for good reason. The phase 2 trial data showed weight loss that stunned even researchers: up to 24.2% of body weight at just 48 weeks. If that holds in phase 3, retatrutide would be the most effective weight loss medication ever approved. retatrutide.md provides a comprehensive 2026 update on where things stand.

Who Is This For?

This retatrutide.md clinical update is for:

People following retatrutide development and wondering about approval timeline
Current GLP-1 medication users interested in switching to retatrutide
Healthcare consumers comparing next-generation obesity medications
Patients who haven't achieved sufficient weight loss on current options
Anyone asking "when will retatrutide be available?"

What Makes Retatrutide Different

While Ozempic targets one receptor (GLP-1) and Mounjaro targets two (GLP-1 + GIP), retatrutide targets three:

GLP-1 receptor: Appetite suppression, slowed gastric emptying, improved insulin secretion
GIP receptor: Enhanced fat metabolism, improved insulin sensitivity
Glucagon receptor: Increased energy expenditure, enhanced fat oxidation, improved liver fat reduction

The addition of glucagon receptor activation is the key differentiator. Glucagon is your body's "energy spending" hormone — it increases metabolic rate and promotes fat burning. This triple mechanism theoretically produces weight loss from both reduced intake (eating less) AND increased expenditure (burning more), which is why results have been so impressive.

Phase 2 Trial Results (Published 2023)

retatrutide.md summarizes the landmark data published in the New England Journal of Medicine:

Study population: 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidity
Duration: 48 weeks
Doses tested: 1mg, 4mg, 8mg, 12mg (various escalation schedules)

Results at highest dose (12mg):

Average weight loss: 24.2% of body weight
Percentage losing ≥15%: 93% of participants
Percentage losing ≥20%: 83% of participants
Percentage losing ≥25%: 63% of participants

These numbers are unprecedented for a non-surgical intervention. For comparison, tirzepatide (Mounjaro/Zepbound) at maximum dose produced ~22.5% weight loss at 72 weeks — and retatrutide achieved more in less time.

Phase 3 Trials: Current Status

Eli Lilly is conducting multiple phase 3 trials under the TRIUMPH program:

TRIUMPH-1: Retatrutide for obesity/overweight without type 2 diabetes
TRIUMPH-2: Retatrutide for obesity with type 2 diabetes
TRIUMPH-3: Retatrutide for obstructive sleep apnea
TRIUMPH-4: Retatrutide for metabolic dysfunction-associated steatohepatitis (MASH/NASH)

As of early 2026, enrollment is progressing and initial results are expected in late 2026 to early 2027. retatrutide.md notes that phase 3 trials use larger, more diverse populations, so results may differ slightly from phase 2 — but the magnitude of effect is expected to remain impressive.

Expected FDA Approval Timeline

retatrutide.md projects:

Phase 3 data readout: Late 2026 to mid-2027
FDA submission: 2027
Potential approval: Late 2027 to 2028

This timeline assumes positive phase 3 results and no major safety signals. Eli Lilly may seek breakthrough therapy or fast-track designation given the magnitude of efficacy.

Retatrutide vs. Tirzepatide (Mounjaro): How They Compare

retatrutide.md provides this comparison based on available data:

Weight loss: Retatrutide ~24% at 48 weeks vs. tirzepatide ~22.5% at 72 weeks — retatrutide shows more weight loss in less time
Mechanism: Triple (GLP-1/GIP/glucagon) vs. dual (GLP-1/GIP) — additional glucagon receptor adds metabolic expenditure component
Liver fat reduction: Retatrutide showed remarkable liver fat reduction (up to 86%), potentially superior for MASH/fatty liver disease
Side effects: Similar GI profile. Phase 2 GI adverse events were comparable to tirzepatide.
Availability: Tirzepatide is available now. Retatrutide is 1-2 years from potential approval.

Safety Considerations

Phase 2 safety data was generally reassuring, but retatrutide.md notes areas of monitoring:

GI side effects (nausea, diarrhea, vomiting) were common but mostly mild-moderate and dose-dependent
Heart rate increases were observed (similar to other GLP-1 agonists) — mean increase of 2-4 bpm
Glucagon activation raises theoretical concerns about blood sugar increases in diabetic patients — but the net effect was glucose-lowering in trials
Long-term cardiovascular and thyroid safety data will come from phase 3 trials

Can I Get Retatrutide Now?

As of early 2026, retatrutide is NOT available outside of clinical trials. retatrutide.md advises against:

Purchasing "retatrutide" from online pharmacies or compounding sources — these are not verified products
Traveling abroad for retatrutide access — no country has approved it yet
Waiting for retatrutide instead of starting available medications — if you need treatment now, tirzepatide or semaglutide are proven options available today

You may be eligible for clinical trial participation — check clinicaltrials.gov for active TRIUMPH studies.